<DOC>
	<DOC>NCT02873936</DOC>
	<brief_summary>The primary objective of this study is to evaluate the effects of filgotinib versus placebo in adults with active rheumatoid arthritis (RA) who have an inadequate response to biologic disease-modifying anti-rheumatic drug(s) (DMARDs) treatment.</brief_summary>
	<brief_title>Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Have a diagnosis of RA (2010 ACR/EULAR criteria for RA), and are ACR functional class IIII. Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥6 tender joints (from a tender joint count based on 68 joints (TJC68)) at screening and Day 1 Ongoing treatment with a stable prescription of 1 or 2 csDMARDs Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for the treatment of RA to which they have had an inadequate response or intolerance Previous treatment with any janus kinase (JAK) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>